読み込み中
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
終値時点
$6.89
−$1.06 · -13.33%
時間外
$7.0526
+$0.1626 · +2.36%
10月13日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日中レンジ
現在 $6.89
52週レンジ
現在 $6.89
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
33
割高
センチメント
50
まちまち
リスク
50
やや高いリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
日中レンジ
現在 $6.89
52週レンジ
現在 $6.89
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$22.13
上昇余地（221.19%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI630.56万0.00%2.3兆 USD0.03%$381.32-0.07%
Vanguard Extended Market ETFVXF251.61万0.00%954億 USD0.05%$232.54-0.42%
iShares Micro-Cap ETFIWC34.32万0.03%13.07億 USD0.60%$179.6-1.13%
Simplify Propel Opportunities ETFSURI24.43万0.32%7546.43万 USD2.82%$17.09-0.96%
Avantis U.S. Small Cap Equity ETFAVSC13.93万—30.79億 USD0.25%$70.06+0.13%
ALPS Medical Breakthroughs ETFSBIO13.47万0.07%1.87億 USD0.50%$51.64-4.10%
Invesco NASDAQ Future Gen 200 ETFQQQS6.18万0.27%2275.83万 USD0.20%$40.5723-2.03%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIAvantis U.S. Small Cap Equity ETFAVSCALPS Medical Breakthroughs ETFSBIOInvesco NASDAQ Future Gen 200 ETFQQQSAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
